Corient Private Wealth LLC Invests $239,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Corient Private Wealth LLC purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,829 shares of the company's stock, valued at approximately $239,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Meridian Wealth Management LLC grew its holdings in shares of Axsome Therapeutics by 0.7% during the fourth quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company's stock worth $1,791,000 after purchasing an additional 150 shares during the last quarter. Arizona State Retirement System grew its holdings in Axsome Therapeutics by 1.8% during the 4th quarter. Arizona State Retirement System now owns 9,054 shares of the company's stock worth $766,000 after acquiring an additional 164 shares during the last quarter. KBC Group NV grew its holdings in Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after acquiring an additional 385 shares during the last quarter. Assetmark Inc. acquired a new stake in Axsome Therapeutics in the 4th quarter valued at about $52,000. Finally, R Squared Ltd bought a new position in shares of Axsome Therapeutics in the fourth quarter worth about $64,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AXSM has been the subject of a number of research reports. Leerink Partners raised their price target on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a report on Monday, February 10th. HC Wainwright restated a "buy" rating and set a $200.00 target price on shares of Axsome Therapeutics in a research report on Thursday. Royal Bank of Canada raised their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the company an "outperform" rating in a report on Wednesday, February 19th. Wells Fargo & Company boosted their price objective on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Finally, Morgan Stanley raised their target price on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $167.64.

Remove Ads

Axsome Therapeutics Stock Down 8.4 %

Shares of AXSM traded down $9.03 on Friday, hitting $98.86. The company's stock had a trading volume of 990,570 shares, compared to its average volume of 664,839. The firm's fifty day moving average price is $120.62 and its 200-day moving average price is $101.67. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The firm has a market capitalization of $4.82 billion, a price-to-earnings ratio of -16.50 and a beta of 0.88.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. The company had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. On average, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Transactions at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.40% of the stock is owned by insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.